A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of BMC128 in combination
with nivolumab (a known immunotherapy) in order to investigate if administration of select
elements of the intestinal microbiome may serve as a novel and effective means of improving
the efficacy of anti-cancer immunotherapies.